

Special Issue

The Development of mRNA Vaccines

Message from the Guest Editors

mRNA vaccines have emerged as a transformative platform in modern medicine, demonstrating remarkable success in combating infectious diseases, such as COVID-19 and RSV. This Special Issue aims to explore the latest advancements in mRNA vaccine research, encompassing a wide range of applications, from infectious disease prevention to tumor immunity. Topics of interest include innovative mRNA delivery systems that enhance stability and efficiency, novel vaccine designs targeting emerging pathogens and cancer antigens, and the development of next-generation adjuvants to optimize immune responses. Additionally, we welcome studies addressing manufacturing scalability, regulatory challenges, and strategies to broaden mRNA vaccine accessibility. By showcasing cutting-edge research, this Special Issue seeks to advance the field and inspire new approaches to address global health challenges.

Guest Editors

Dr. Minghui Yang

Dr. Yuming Li

Dr. Bo Hu

Deadline for manuscript submissions

31 December 2025



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/227986

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).